Bioengineering approaches to study multidrug resistance in tumor cells.
暂无分享,去创建一个
[1] S. Fuqua,et al. Expression of the K303R estrogen receptor-alpha breast cancer mutation induces resistance to an aromatase inhibitor via addiction to the PI3K/Akt kinase pathway. , 2009, Cancer research.
[2] V. Valero,et al. Phase II multicenter study of larotaxel (XRP9881), a novel taxoid, in patients with metastatic breast cancer who previously received taxane-based therapy. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.
[3] Ronald A. DePinho,et al. Model organisms: The mighty mouse: genetically engineered mouse models in cancer drug development , 2006, Nature Reviews Drug Discovery.
[4] I. Vergote,et al. Randomized phase III study of canfosfamide (C, TLK286) plus pegylated liposomal doxorubicin (PLD) versus PLD as second-line therapy in platinum (P) refractory or resistant ovarian cancer (OC). , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] Martin G Pomper,et al. Can small animal imaging accelerate drug development? , 2002, Journal of cellular biochemistry. Supplement.
[6] T. Kunkel,et al. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. , 1998, Cancer research.
[7] D. Tarin,et al. Significance of CD44 gene products for cancer diagnosis and disease evaluation , 1992, The Lancet.
[8] E. Winer,et al. A phase II trial of the PARP inhibitor veliparib (ABT888) and temozolomide for metastatic breast cancer. , 2010 .
[9] R. Kerbel,et al. Adhesion-dependent multicellular drug resistance. , 1999, Anti-cancer drug design.
[10] R. Kerbel,et al. Reversal by hyaluronidase of adhesion-dependent multicellular drug resistance in mammary carcinoma cells. , 1996, Journal of the National Cancer Institute.
[11] J. Doroshow,et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. , 2001, Blood.
[12] Marcus Textor,et al. Engineered 3D environments to elucidate the effect of environmental parameters on drug response in cancer. , 2011, Integrative biology : quantitative biosciences from nano to macro.
[13] Emil Frei,et al. Studies of Sequential and Combination Antimetabolite Therapy in Acute Leukemia: 6-Mercaptopurine and Methotrexate , 1961 .
[14] G. Melillo,et al. Inhibiting Hypoxia-Inducible Factor 1 for Cancer Therapy , 2006, Molecular Cancer Research.
[15] P. Carmeliet,et al. Mechanisms of resistance to anti-angiogenic therapy and development of third-generation anti-angiogenic drug candidates. , 2010, Genes & cancer.
[16] G. Denis. Imatinib Mesylate (Gleevec®) and the Emergence of Chemotherapeuticss Drug-Resistant Mutations , 2008 .
[17] G. Semenza. Targeting HIF-1 for cancer therapy , 2003, Nature Reviews Cancer.
[18] J. Damiano,et al. Integrins as novel drug targets for overcoming innate drug resistance. , 2002, Current cancer drug targets.
[19] Max S Wicha,et al. Cancer stem cells: an old idea--a paradigm shift. , 2006, Cancer research.
[20] S. Fulda,et al. Role of hypoxia inducible factor-1 alpha in modulation of apoptosis resistance , 2007, Oncogene.
[21] M. Poupon,et al. Distinctive alterations of invasiveness, drug resistance and cell–cell organization in 3D-cultures of MCF-7, a human breast cancer cell line, and its multidrug resistant variant , 2004, Clinical & Experimental Metastasis.
[22] L. Panasci,et al. DNA-Dependent protein kinase activity correlates with clinical and in vitro sensitivity of chronic lymphocytic leukemia lymphocytes to nitrogen mustards. , 1998, Blood.
[23] M. Mimeault,et al. Recent Advances on the Molecular Mechanisms Involved in the Drug Resistance of Cancer Cells and Novel Targeting Therapies , 2008, Clinical pharmacology and therapeutics.
[24] J. Surrallés,et al. The Fanconi Anemia/BRCA Pathway: FANCD2 at the Crossroad between Repair and Checkpoint Responses to DNA Damage , 2006 .
[25] I. Weissman,et al. Stem cells, cancer, and cancer stem cells , 2001, Nature.
[26] Christopher Haslett,et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: A mechanism for small cell lung cancer growth and drug resistance in vivo , 1999, Nature Medicine.
[27] R. Sutherland,et al. Cell contact as a possible contribution to radiation resistance of some tumours. , 1972, The British journal of radiology.
[28] Celeste M Nelson,et al. Cell‐cell signaling by direct contact increases cell proliferation via a PI3K‐dependent signal , 2002, FEBS letters.
[29] I. Pastan,et al. Expression of a full-length cDNA for the human "MDR1" gene confers resistance to colchicine, doxorubicin, and vinblastine. , 1987, Proceedings of the National Academy of Sciences of the United States of America.
[30] P. Karran. Mechanisms of tolerance to DNA damaging therapeutic drugs. , 2001, Carcinogenesis.
[31] P B Laub,et al. Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. , 1997, Cancer research.
[32] P. Ratcliffe,et al. Activation of the HIF pathway in cancer. , 2001, Current opinion in genetics & development.
[33] Michael Dean,et al. Tumour stem cells and drug resistance , 2005, Nature Reviews Cancer.
[34] R. Kerbel,et al. Antiadhesive antibodies targeting E-cadherin sensitize multicellular tumor spheroids to chemotherapy in vitro. , 2004, Molecular cancer therapeutics.
[35] B. Teicher,et al. Acquired multicellular-mediated resistance to alkylating agents in cancer. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[36] G. Tortora,et al. In vitro expansion of human breast cancer epithelial and mesenchymal stromal cells: optimization of a coculture model for personalized therapy approaches , 2007, Molecular Cancer Therapeutics.
[37] N. Altorki,et al. TGF-β IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer , 2010, Proceedings of the National Academy of Sciences.
[38] Z. Wang,et al. β2-integrins mediate a novel form of chemoresistance in cycloheximide-induced U937 apoptosis , 2004, Cellular and Molecular Life Sciences CMLS.
[39] Yuan Zhang,et al. Coculture of bladder urothelial and smooth muscle cells on small intestinal submucosa: potential applications for tissue engineering technology. , 2000, The Journal of urology.
[40] D. Hanahan,et al. The Hallmarks of Cancer , 2000, Cell.
[41] S. Sahoo,et al. 3-D tumor model for in vitro evaluation of anticancer drugs. , 2008, Molecular pharmaceutics.
[42] A. Puisieux,et al. Metastasis: a question of life or death , 2006, Nature Reviews Cancer.
[43] S. Kaufmann,et al. PARP inhibition: PARP1 and beyond , 2010, Nature Reviews Cancer.
[44] H. Beug,et al. Molecular requirements for epithelial-mesenchymal transition during tumor progression. , 2005, Current opinion in cell biology.
[45] A. Beitz,et al. Secretion of MCP-1 and other paracrine factors in a novel tumor-bone coculture model , 2009, BMC Cancer.
[46] M. Dewhirst,et al. Concepts of oxygen transport at the microcirculatory level. , 1998, Seminars in radiation oncology.
[47] D. Altieri. Survivin, versatile modulation of cell division and apoptosis in cancer , 2003, Oncogene.
[48] L. Griffith,et al. Capturing complex 3D tissue physiology in vitro , 2006, Nature Reviews Molecular Cell Biology.
[49] R L Juliano,et al. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. , 1976, Biochimica et biophysica acta.
[50] C. S. Chen,et al. Geometric control of cell life and death. , 1997, Science.
[51] Guang-Biao Zhou,et al. Treatment of acute promyelocytic leukaemia with all-trans retinoic acid and arsenic trioxide: a paradigm of synergistic molecular targeting therapy , 2007, Philosophical Transactions of the Royal Society B: Biological Sciences.
[52] P. Zinzani,et al. Phase I/II trial of a P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin's lymphoma , 2007, Leukemia & lymphoma.
[53] J. Brown,et al. Exploiting tumour hypoxia in cancer treatment , 2004, Nature Reviews Cancer.
[54] H. Takeuchi,et al. New-generation efflux pump inhibitors , 2008, Expert review of clinical pharmacology.
[55] S. Cole,et al. Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. , 2006, Physiological reviews.
[56] H. Chakrapani,et al. Synthesis, nitric oxide release, and anti-leukemic activity of glutathione-activated nitric oxide prodrugs: Structural analogues of PABA/NO, an anti-cancer lead compound. , 2008, Bioorganic & medicinal chemistry.
[57] C. Sotiriou,et al. Taking gene-expression profiling to the clinic: when will molecular signatures become relevant to patient care? , 2007, Nature Reviews Cancer.
[58] D. Hussein,et al. Chronic hypoxia promotes hypoxia-inducible factor-1α–dependent resistance to etoposide and vincristine in neuroblastoma cells , 2006, Molecular Cancer Therapeutics.
[59] S. Gerson. MGMT: its role in cancer aetiology and cancer therapeutics , 2004, Nature Reviews Cancer.
[60] C. L. La Porta,et al. Cancer stem cells and therapeutic perspectives. , 2006, Current medicinal chemistry.
[61] J. Ioannidis,et al. The association of P‐glycoprotein with response to chemotherapy and clinical outcome in patients with osteosarcoma , 2003, Cancer.
[62] Y. Hishikawa,et al. Overexpression of metallothionein correlates with chemoresistance to cisplatin and prognosis in esophageal cancer. , 1997, Oncology.
[63] Richard P. Hill,et al. The hypoxic tumour microenvironment and metastatic progression , 2004, Clinical & Experimental Metastasis.
[64] D. Durocher,et al. DNA-PK, ATM and ATR as sensors of DNA damage: variations on a theme? , 2001, Current opinion in cell biology.
[65] T. Sakaeda,et al. An update on overcoming MDR1-mediated multidrug resistance in cancer chemotherapy. , 2006, Current pharmaceutical design.
[66] G. Semenza,et al. Regulation of colon carcinoma cell invasion by hypoxia-inducible factor 1. , 2003, Cancer research.
[67] A. Rzhetsky,et al. The human ATP-binding cassette (ABC) transporter superfamily. , 2001, Genome research.
[68] R. Arceci,et al. Phase I study of valspodar (PSC‐833) with mitoxantrone and etoposide in refractory and relapsed pediatric acute leukemia: A report from the Children's Oncology Group , 2010, Pediatric blood & cancer.
[69] L. Matrisian,et al. Matrix metalloproteinases in tumor-host cell communication. , 2002, Differentiation; research in biological diversity.
[70] R. Ozols,et al. Phase I study of thiotepa in combination with the glutathione transferase inhibitor ethacrynic acid. , 1991, Cancer Research.
[71] A. Townsend,et al. Dynamics of glutathione conjugation and conjugate efflux in detoxification of the carcinogen, 4-nitroquinoline 1-oxide: contributions of glutathione, glutathione S-transferase, and MRP1. , 2005, Biochemistry.
[72] J. Hardwick,et al. Upgrading the BCL-2 Network , 2006, Nature Cell Biology.
[73] R J Carroll,et al. Phase II clinical trial design for noncytotoxic anticancer agents for which time to disease progression is the primary endpoint. , 2000, Controlled clinical trials.
[74] A. Strasser,et al. The BCL-2 protein family: opposing activities that mediate cell death , 2008, Nature Reviews Molecular Cell Biology.
[75] G. Giaccone,et al. A Phase I Safety and Pharmacologic Study of a Twice Weekly Dosing Regimen of the Oral Taxane BMS-275183 , 2007, Clinical Cancer Research.
[76] J. Tschopp,et al. The Long Form of FLIP Is an Activator of Caspase-8 at the Fas Death-inducing Signaling Complex* , 2002, The Journal of Biological Chemistry.
[77] Michael L Maitland,et al. Terminal Ballistics of Kinase Inhibitors: There Are No Magic Bullets , 2006, Annals of Internal Medicine.
[78] M. Mimeault,et al. Interplay of distinct growth factors during epithelial mesenchymal transition of cancer progenitor cells and molecular targeting as novel cancer therapies. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.
[79] W. V. van Weerden,et al. Use of nude mouse xenograft models in prostate cancer research , 2000, The Prostate.
[80] B. Cheson,et al. Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist, in patients with advanced chronic lymphocytic leukemia. , 2009, Blood.
[81] J. Rosen,et al. Stem cells in the etiology and treatment of cancer. , 2006, Current opinion in genetics & development.
[82] O. Olopade,et al. FANCF methylation contributes to chemoselectivity in ovarian cancer. , 2003, Cancer Cell.
[83] Qingcheng Mao,et al. Role of the breast cancer resistance protein (ABCG2) in drug transport , 2005, The AAPS Journal.
[84] K. Shakesheff,et al. Liver tissue engineering: a role for co-culture systems in modifying hepatocyte function and viability. , 2001, Tissue engineering.
[85] D. McDonald,et al. Abnormalities of basement membrane on blood vessels and endothelial sprouts in tumors. , 2003, The American journal of pathology.
[86] Jean-Pierre Gillet,et al. Mechanisms of multidrug resistance in cancer. , 2010, Methods in molecular biology.
[87] K. Black,et al. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma , 2006, Molecular Cancer.
[88] J. Erler,et al. Reversing Hypoxic Cell Chemoresistance in Vitro Using Genetic and Small Molecule Approaches Targeting Hypoxia Inducible Factor-1 , 2006, Molecular Pharmacology.
[89] S. Kaye,et al. Drug resistance reversal--are we getting closer? , 2003, European journal of cancer.
[90] R. Bociek,et al. Randomized phase III trial of fludarabine plus cyclophosphamide with or without oblimersen sodium (Bcl-2 antisense) in patients with relapsed or refractory chronic lymphocytic leukemia. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[91] D. Hamer,et al. Overexpression of metallothionein confers resistance to anticancer drugs. , 1988, Science.
[92] M. Mimeault,et al. Concise Review: Recent Advances on the Significance of Stem Cells in Tissue Regeneration and Cancer Therapies , 2006, Stem cells.
[93] C. S. Chen,et al. Control of cyclin D1, p27(Kip1), and cell cycle progression in human capillary endothelial cells by cell shape and cytoskeletal tension. , 1998, Molecular biology of the cell.
[94] M. Textor,et al. single cells{ , 2007 .
[95] Michael C. Ostrowski,et al. Genomic alterations in tumor stroma. , 2009, Cancer research.
[96] M. Gottesman,et al. Multidrug resistance in cancer: role of ATP–dependent transporters , 2002, Nature Reviews Cancer.
[97] A. Pandey,et al. Identification of secreted proteins that mediate cell-cell interactions in an in vitro model of the lung cancer microenvironment. , 2008, Cancer research.
[98] F. Alt,et al. Defective DNA-dependent protein kinase activity is linked to V(D)J recombination and DNA repair defects associated with the murine scid mutation , 1995, Cell.
[99] Frank Pajonk,et al. The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation. , 2006, Journal of the National Cancer Institute.
[100] D. Townsend,et al. The role of glutathione-S-transferase in anti-cancer drug resistance , 2003, Oncogene.
[101] Monica Hoyos Flight. Drug screening: Shedding light on tumour–stroma interactions , 2010, Nature Reviews Drug Discovery.
[102] Ian F Tannock,et al. The influence of P-glycoprotein expression and its inhibitors on the distribution of doxorubicin in breast tumors , 2009, BMC Cancer.
[103] B. Toole,et al. Interactions between human tumor cells and fibroblasts stimulate hyaluronate synthesis. , 1984, Proceedings of the National Academy of Sciences of the United States of America.
[104] U Kneser,et al. Modulation of in vitro angiogenesis in a three-dimensional spheroidal coculture model for bone tissue engineering. , 2004, Tissue engineering.
[105] Z. Estrov,et al. Eradication of Leukemia Stem Cells as a New Goal of Therapy in Leukemia , 2006, Clinical Cancer Research.
[106] Jiaquan Xu,et al. Deaths: final data for 2006. , 2009, National vital statistics reports : from the Centers for Disease Control and Prevention, National Center for Health Statistics, National Vital Statistics System.
[107] D. Fisher,et al. A CD44 survival pathway triggers chemoresistance via lyn kinase and phosphoinositide 3-kinase/Akt in colon carcinoma cells. , 2001, Cancer research.
[108] D. Gandara,et al. Tirapazamine: prototype for a novel class of therapeutic agents targeting tumor hypoxia. , 2002, Seminars in oncology.
[109] R. Herbst,et al. Results from a phase I, dose-escalation study of PX-478, an orally available inhibitor of HIF-1{alpha}. , 2010 .
[110] W. Dalton. The tumor microenvironment as a determinant of drug response and resistance. , 1999, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.
[111] A. Tutt,et al. Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[112] Crispin J. Miller,et al. Hypoxia-Mediated Down-Regulation of Bid and Bax in Tumors Occurs via Hypoxia-Inducible Factor 1-Dependent and -Independent Mechanisms and Contributes to Drug Resistance , 2004, Molecular and Cellular Biology.
[113] J. Xu,et al. Extracellular matrix alters PDGF regulation of fibroblast integrins , 1996, The Journal of cell biology.
[114] J. Massagué,et al. Beyond tumorigenesis: cancer stem cells in metastasis , 2007, Cell Research.
[115] James M. Roberts,et al. Adhesion-dependent cell cycle progression linked to the expression of cyclin D1, activation of cyclin E-cdk2, and phosphorylation of the retinoblastoma protein , 1996, The Journal of cell biology.
[116] Yoshimasa Tanaka,et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[117] A. Zhu,et al. Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors , 2007, Cancer Chemotherapy and Pharmacology.
[118] C. Craddock,et al. Repair of DNA interstrand crosslinks as a mechanism of clinical resistance to melphalan in multiple myeloma. , 2000, Blood.
[119] K. Anderson,et al. Tumor cell-specific bioluminescence platform to identify stroma-induced changes to anti-cancer drug activity , 2010, Nature Medicine.